A client texts you a photo of the scale. They’re down 9 kilos in eight weeks. They’re thrilled. You should be too — except a quarter to nearly half of what they just lost wasn’t fat.
That’s not a scare statistic. It’s what the registration trials for these drugs actually show. And it turns the GLP-1 boom into something most coaches aren’t prepared for: a wave of clients who are losing weight fast, feel like they’re winning, and are quietly dismantling the exact tissue that keeps them healthy, mobile, and metabolically resilient.
The drug isn’t the enemy here. The gap in monitoring is.
What the scale isn’t telling you
GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and the dual GLP-1/GIP agonist tirzepatide (Mounjaro, Zepbound) — work by mimicking a gut hormone that regulates appetite and blood sugar. The result is rapid, substantial weight loss, often faster than anything achievable through diet and training alone.
The problem is what comes off. Across the major trials, lean mass consistently accounts for a meaningful chunk of total weight lost:
- In the STEP-1 trial of semaglutide, lean mass dropped by roughly 13%, working out to around 45% of total weight lost coming from lean tissue.
- In the SURMOUNT-1 trial of tirzepatide, the fraction was lower but still significant — about 26% of total weight lost from lean mass.
- Meta-analyses landing around 25–40% of total weight loss as lean mass, depending on the drug, dose, and population.
A fair caveat, because credibility matters: some of that “lean mass” figure includes water and other tissue, not pure muscle, and as a proportion of total body mass, lean tissue often holds steady or even improves. For many patients this is partly adaptive — a smaller body needs less muscle to move it around. This is not muscle wasting disease.
But “adaptive on average” is cold comfort for the individual client sitting in front of you who’s losing strength, whose resting metabolic rate is dropping, and who will regain fat far more easily on a shrunken muscle base if they ever come off the drug. The absolute muscle loss is real, and for older clients or those already low on muscle, it’s a genuine functional threat.
The Scale Lies — Body Composition Simulator
Why this is a training problem, not just a drug problem
Here’s the part that should interest every coach: the lean mass loss is largely modifiable. The two levers that protect muscle through any large deficit are well established — adequate protein and progressive resistance training. The drug creates the deficit; what the client does inside that deficit decides whether they come out the other side strong or hollowed out.
That puts coaches squarely in the picture. A GLP-1 client who lifts properly and eats enough protein can shift the body-composition math dramatically — keeping most of the muscle while the fat falls away. A GLP-1 client running a generic plan, or no plan, is the one feeding the 45% statistic.
So the opportunity is obvious. The execution is where it gets hard.
Why a standard training template fails the GLP-1 client
You cannot run a GLP-1 client like a normal client, and this is the piece most coaches miss.
A typical client in maintenance or a mild deficit has stable capacity. You can hand them a linear progression — add a little load each week, hit your prescribed sets — and trust they’ll roughly keep up. The plan is a reasonable predictor of what their body can do.
A GLP-1 client is the opposite. They’re in a large, sustained energy deficit with pharmacologically suppressed appetite. Their available energy, recovery, and tolerance for load swing hard from week to week — sometimes day to day — depending on how much they managed to eat, how the nausea hit, where they are in the dose-escalation schedule. Capacity is a moving target.
Push a fixed progression onto that moving target and you get the worst of both worlds:
- On low-capacity weeks, the prescribed load is too much. The client grinds through sessions at a far higher effort than planned, accumulates fatigue they can’t recover from, feels terrible, and — the real risk — drops out. The adherence research on resistance training is brutal; the clients who feel buried quit.
- On higher-capacity weeks, a conservatively templated plan leaves stimulus on the table. Not enough mechanical tension to defend muscle against the deficit. The session “happened” but didn’t do its one job.
The fix isn’t a better template. It’s no fixed template at all. It’s autoregulation — titrating each session’s load to the client’s actual readiness that day, using how hard the work actually felt (RPE) against how hard it was supposed to feel. Keep the real stimulus inside the effective band, week after week, regardless of how capacity is bouncing around.
Fixed Plan vs. Adaptive Plan — GLP-1 Client Training
What coaches should actually monitor
If bodyweight is the wrong signal — and for a GLP-1 client it is actively misleading, because it’s supposed to go down — what should you track instead?
- Strength markers, not scale weight. Are key lifts holding or progressing through the deficit? Maintained strength is your best practical proxy that muscle is being defended. Falling strength is the early warning that the 45% scenario is unfolding.
- RPE drift. When sessions that used to sit at a 7 start feeling like a 9 at the same loads, capacity is dropping and the program needs to flex now, not at the next monthly check-in.
- Completion and adherence. Missed sets and abandoned sessions are data, not noise. They’re usually the first visible sign a client is being pushed past what the deficit allows.
None of these is exotic. The catch is that they have to be tracked per client, every session, and acted on quickly — because with a fluctuating GLP-1 client, last week’s read is already stale.
The collision no one’s pricing in
Now put the two facts together.
GLP-1 medications are bringing a flood of new clients into coaching — people who’ve lost the initial weight and now want to keep the muscle, look strong, and not bounce back. That’s the quantity side.
And every one of those clients needs more individual attention than a standard client, not less: finer-grained monitoring, faster program adjustments, closer reading of fluctuating capacity.
More clients, each demanding tighter individualization. That’s the precise pressure point where manual coaching breaks. A coach with 15 stable clients can hold quality. The same coach with 40 GLP-1 clients — each needing per-session load adjustments off strength trends and RPE drift — cannot. Not by hand. The monitoring that protects muscle is exactly the thing that doesn’t scale, so quality quietly collapses just as the client volume climbs. Spreadsheets and memory don’t survive that math.
What to Do Right Now
If you have GLP-1 clients and you haven’t changed how you’re programming them, here’s where to start:
1. Audit their strength trends. Pull up their logged weights from the last 6–8 weeks. Are they holding? Slowly declining? A consistent 5% drop in key compound lifts is a signal worth acting on immediately.
2. Switch to RPE-based programming. Fixed percentages assume a stable baseline. Your GLP-1 clients don’t have a stable baseline. Set target RPE ranges and let the client’s actual response drive the load.
3. Reduce volume before you reduce intensity. When a GLP-1 client is clearly under-recovered, the instinct is often to drop the weight. That’s wrong. You want to keep intensity high enough to maintain the anabolic signal — reduce sets and sessions first, not load.
4. Watch the gap between how they look and how they’re performing. If appearance is improving but performance is quietly declining, the scale win may be hiding a muscle loss problem. The training data tells the real story.
5. Build in explicit check-ins around medication cycles. Some clients dose weekly. In the days after a dose, appetite suppression is often most severe and caloric intake drops sharply. That’s a predictable low-capacity window — and it’s worth knowing where it falls in your training week.
The GLP-1 wave isn’t a trend that’s going to fade. It’s a permanent feature of the coaching landscape now. The coaches who adapt their programming to what these clients actually need will protect outcomes. The ones who keep running standard templates will watch their clients’ scale numbers go down — and eventually notice the performance following.
The scale doesn’t know what it’s losing. You do.
References
- Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine. 2021;384(11):989–1002. https://pubmed.ncbi.nlm.nih.gov/33567185/ (STEP-1 trial — lean mass loss data)
- Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine. 2022;387(3):205–216. https://pubmed.ncbi.nlm.nih.gov/35658024/ (SURMOUNT-1 trial — lean mass loss data)
- Bellicha A, et al. “Effect of exercise training on weight loss, body composition changes, and weight maintenance in adults with overweight or obesity: An overview of 12 systematic reviews and 149 studies.” Obesity Reviews. 2021;22(S4):e13256. https://pubmed.ncbi.nlm.nih.gov/33955140/ (lean mass loss range 25–40% without resistance training)
- Zhao X, et al. “GLP-1 receptor agonists and the risk of muscle mass loss: a systematic review.” Obesity Reviews. 2023. (meta-analysis on lean mass loss across GLP-1 trials)
- Lalia AZ, et al. “Resistance training preserves lean mass during weight loss in older adults.” Obesity. 2021;29(1):56–65. https://pubmed.ncbi.nlm.nih.gov/33159440/ (resistance training vs aerobic — lean mass outcomes)
Leave a Reply
You must be logged in to post a comment.